TGFB1 and early-onset autosomal dominant Alzheimer disease: Besides, both AA and NG have several clinical studies such as using NG in hypercholesterolaemic and overweight human subjects and using AA in patients with Alzheimer's disease, both AA and NG show no adverse effects in the studies40, 41, 42; highlighting its translational potential for targeting the TGF‐β1 signalling in cancer.